iShares MSCI Indonesia ETF vs Nuvation Bio Inc. Class A Common Stock — how do they compare? iShares MSCI Indonesia ETF trades at $12.41 (market cap $410.85M), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Nuvation Bio Inc. Class A Common Stock is far larger — about 4.2× iShares MSCI Indonesia ETF's market cap, and iShares MSCI Indonesia ETF is more actively traded (726,664 versus 5,448,712). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| EIDO | NUVB | |
|---|---|---|
Market Cap | $410.85M | $1.71B |
Volume | 726,664 | 5,448,712 |
52-Week High | $19.22 | $9.54 |
52-Week Low | $10.80 | $3.41 |
Typical Hold Time | 75 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $1.30B |
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.86, down 0.59% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings but faces weak price action despite potential valuation appeal. Recent news highlights foreign capital rotation away from Asian equities and Indonesia's limited benefit from commodity gains.
Outlook remains cautious due to technical downtrend and sector concentration risks. The 44% financials weighting and modest EPS growth constrain upside, though seasonal patterns may offer temporary support. Key risks include regional market volatility and dependence on commodity cycles.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →